100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44EY031642
Award Date
6/1/20
Completion Date
5/31/25
Dollars Obligated
$4.1M
Overview
Activity
10
Transactions
10
Subawards
Similar Awards
Federal Agency
National Eye Institute
Awardee
Nanoscope Technologies LLC (H6DNZXT5MMT1)
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Texas, USA
Update #1
Update #2
TARGETED NANO-ENHANCED OPTICAL DELIVERY OF OPSIN FOR DRY-AMD THERAPY
Posted 5/28/20
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
TARGETED NANO-ENHANCED OPTICAL DELIVERY OF OPSIN FOR DRY-AMD THERAPY - GEOGRAPHIC ATROPHIES (GA) IN DRY-AGE RELATED MACULAR DEGENERATION (AMD) IS CHARACTERIZED BY DEGENERATION OF PHOTORECEPTORS, AND IS THE LEADING CAUSE OF NEW VISION LOSS IN ~15 MILLION PERSONS. THERE IS NEITHER A CURE THAT CAN STOP THE DEGENERATION NOR A THERAPY TO RESTORE VISION LOSS. WE HAVE DEVELOPED AMBIENT-LIGHT ACTIVATABLE MULTI-CHARACTERISTIC OPSIN (MCO-II) TO ALLOW STIMULATION OF RETINAL GANGLION CELLS (RGCS) FOR VISION REHABILITATION. HOWEVER, CLINICAL TRANSLATION OF SUCH GENE THERAPY TO PATIENTS WITH GA WILL REQUIRE TARGETED DELIVERY OF OPSIN- ENCODING GENES INTO THE ATROPHIC REGIONS WITHOUT PERTURBING REMAINING FUNCTIONAL RETINA. THEREFORE, WE HAVE DEVELOPED A NEAR-INFRARED LASER BASED EFFICIENT METHOD FOR IN-VIVO TARGETED GENE DELIVERY INTO RETINA. IN THIS NANO-ENHANCED OPTICAL DELIVERY (NOD) METHOD, WE UTILIZE SURFACE PLASMON RESONANCE BASED FIELD ENHANCEMENT BY FUNCTIONALIZED GOLD NANORODS (FGNRS) TO TRANSIENTLY PERFORATE CELL MEMBRANE TO DELIVER THE MOLECULES. IN THE PHASE I, WE DEMONSTRATED TARGETED IN-VIVO OPTICAL DELIVERY OF MCO-II TO DEGENERATED RETINA IN MICE USING NOD AT MULTIPLE WAVELENGTHS. FURTHER, WE MADE COMPARATIVE STUDY OF CONTINUOUS WAVE (CW) AND NANOSECOND PULSED LASER BASED NOD OF MCO-II PLASMIDS AND DETERMINED OPTIMIZED LASER PARAMETERS FOR EFFICIENT TRANSFECTION OF RETINA. NO DETECTABLE OCULAR DAMAGE WAS OBSERVED DUE TO NOD. FURTHER, THE IMMUNOSTAINING OF RETINA AFTER IN-VIVO NOD OF MCO-II PLASMIDS SHOWED NO NOTICEABLE CELL DEATH. ELECTROPHYSIOLOGY STUDIES DEMONSTRATE THAT MCO-II SENSITIZED CELLS ARE ACTIVATABLE BY LIGHT, ALLOWING VISUALLY EVOKED CORTICAL ACTIVITIES. THE OVERALL GOAL OF THIS PHASE-II PROPOSAL IS TO DEVELOP THE COMBINATION NOD PRODUCT FOR PHOTOSENSITIZING RGCS IN THE DEGENERATED RETINA IN A SAFE MANNER AND STIMULATING PHOTOSENSITIZED RGCS BY AMBIENT LIGHT FOR VISION REHABILITATION. TOWARDS THIS GOAL WE HAVE FOLLOWING AIMS: (1) QUANTIFY LONG-TERM STABILITY AND SAFETY OF NOD IN MICE MODEL LACKING PHOTORECEPTORS; (2) EVALUATE FUNCTIONING OF TARGETED RETINAL REGIONS AFTER RE-PHOTOSENSITIZATION OF RGCS USING NOD ASSISTED MCO-II DELIVERY IN MICE AND RAT MODELS; AND (3) GLP STUDY OF TOXICITY, BIODISTRIBUTION AND EFFICACY OF NOD-DELIVERED MCO-II PLASMIDS IN NON-HUMAN PRIMATES (NHPS). THIS COLLABORATIVE PROPOSAL BRINGS TOGETHER COMPLEMENTARY EXPERTISE IN OPTICAL DELIVERY, OPTOGENETICS, OPHTHALMOLOGY, INSTRUMENT, MOLECULAR BIOLOGY, NANOMATERIALS, RETINA BIOLOGY AND FUNCTION, NEUROSCIENCE/BEHAVIOR, ELECTROPHYSIOLOGY, BIOSTATISTICS, AND TOXICOLOGY TO ADDRESS THE CHALLENGE IN RETINAL DEGENERATION. THE SAFETY/EFFICACY STUDY IN NHPS WILL BE PERFORMED AT CRO FACILITY. UPON COMPLETION OF THE PHASE II WE ENVISION TO ADVANCE: (I) NOD PRODUCT DEVELOPMENT FOR CLINICAL STUDIES, (II) IND APPLICATION TO FDA, AND (III) PARTNERING WITH VENTURE CAPITAL AND PHARMA COMPANY FOR COMMERCIALIZATION. SUCCESS OF THIS PROPOSAL WILL LEAD TO A NEW CLINICAL APPROACH FOR TREATING PATIENTS WITH GA BY CONVENTIONAL INTRAVITREAL INJECTION OF FGNRS AND MCO-II. THE NOD BASED TARGETED DELIVERY OF IMPERMEABLE EXOGENOUS MATERIALS (SMALL MOLECULES, PROTEINS AND GENES) WILL BENEFIT DRUG, VACCINE AND GENE THERAPY.
$0
9/29/25
Not listed
TARGETED NANO-ENHANCED OPTICAL DELIVERY OF OPSIN FOR DRY-AMD THERAPY - GEOGRAPHIC ATROPHIES (GA) IN DRY-AGE RELATED MACULAR DEGENERATION (AMD) IS CHARACTERIZED BY DEGENERATION OF PHOTORECEPTORS, AND IS THE LEADING CAUSE OF NEW VISION LOSS IN ~15 MILLION PERSONS. THERE IS NEITHER A CURE THAT CAN STOP THE DEGENERATION NOR A THERAPY TO RESTORE VISION LOSS. WE HAVE DEVELOPED AMBIENT-LIGHT ACTIVATABLE MULTI-CHARACTERISTIC OPSIN (MCO-II) TO ALLOW STIMULATION OF RETINAL GANGLION CELLS (RGCS) FOR VISION REHABILITATION. HOWEVER, CLINICAL TRANSLATION OF SUCH GENE THERAPY TO PATIENTS WITH GA WILL REQUIRE TARGETED DELIVERY OF OPSIN- ENCODING GENES INTO THE ATROPHIC REGIONS WITHOUT PERTURBING REMAINING FUNCTIONAL RETINA. THEREFORE, WE HAVE DEVELOPED A NEAR-INFRARED LASER BASED EFFICIENT METHOD FOR IN-VIVO TARGETED GENE DELIVERY INTO RETINA. IN THIS NANO-ENHANCED OPTICAL DELIVERY (NOD) METHOD, WE UTILIZE SURFACE PLASMON RESONANCE BASED FIELD ENHANCEMENT BY FUNCTIONALIZED GOLD NANORODS (FGNRS) TO TRANSIENTLY PERFORATE CELL MEMBRANE TO DELIVER THE MOLECULES. IN THE PHASE I, WE DEMONSTRATED TARGETED IN-VIVO OPTICAL DELIVERY OF MCO-II TO DEGENERATED RETINA IN MICE USING NOD AT MULTIPLE WAVELENGTHS. FURTHER, WE MADE COMPARATIVE STUDY OF CONTINUOUS WAVE (CW) AND NANOSECOND PULSED LASER BASED NOD OF MCO-II PLASMIDS AND DETERMINED OPTIMIZED LASER PARAMETERS FOR EFFICIENT TRANSFECTION OF RETINA. NO DETECTABLE OCULAR DAMAGE WAS OBSERVED DUE TO NOD. FURTHER, THE IMMUNOSTAINING OF RETINA AFTER IN-VIVO NOD OF MCO-II PLASMIDS SHOWED NO NOTICEABLE CELL DEATH. ELECTROPHYSIOLOGY STUDIES DEMONSTRATE THAT MCO-II SENSITIZED CELLS ARE ACTIVATABLE BY LIGHT, ALLOWING VISUALLY EVOKED CORTICAL ACTIVITIES. THE OVERALL GOAL OF THIS PHASE-II PROPOSAL IS TO DEVELOP THE COMBINATION NOD PRODUCT FOR PHOTOSENSITIZING RGCS IN THE DEGENERATED RETINA IN A SAFE MANNER AND STIMULATING PHOTOSENSITIZED RGCS BY AMBIENT LIGHT FOR VISION REHABILITATION. TOWARDS THIS GOAL WE HAVE FOLLOWING AIMS: (1) QUANTIFY LONG-TERM STABILITY AND SAFETY OF NOD IN MICE MODEL LACKING PHOTORECEPTORS; (2) EVALUATE FUNCTIONING OF TARGETED RETINAL REGIONS AFTER RE-PHOTOSENSITIZATION OF RGCS USING NOD ASSISTED MCO-II DELIVERY IN MICE AND RAT MODELS; AND (3) GLP STUDY OF TOXICITY, BIODISTRIBUTION AND EFFICACY OF NOD-DELIVERED MCO-II PLASMIDS IN NON-HUMAN PRIMATES (NHPS). THIS COLLABORATIVE PROPOSAL BRINGS TOGETHER COMPLEMENTARY EXPERTISE IN OPTICAL DELIVERY, OPTOGENETICS, OPHTHALMOLOGY, INSTRUMENT, MOLECULAR BIOLOGY, NANOMATERIALS, RETINA BIOLOGY AND FUNCTION, NEUROSCIENCE/BEHAVIOR, ELECTROPHYSIOLOGY, BIOSTATISTICS, AND TOXICOLOGY TO ADDRESS THE CHALLENGE IN RETINAL DEGENERATION. THE SAFETY/EFFICACY STUDY IN NHPS WILL BE PERFORMED AT CRO FACILITY. UPON COMPLETION OF THE PHASE II WE ENVISION TO ADVANCE: (I) NOD PRODUCT DEVELOPMENT FOR CLINICAL STUDIES, (II) IND APPLICATION TO FDA, AND (III) PARTNERING WITH VENTURE CAPITAL AND PHARMA COMPANY FOR COMMERCIALIZATION. SUCCESS OF THIS PROPOSAL WILL LEAD TO A NEW CLINICAL APPROACH FOR TREATING PATIENTS WITH GA BY CONVENTIONAL INTRAVITREAL INJECTION OF FGNRS AND MCO-II. THE NOD BASED TARGETED DELIVERY OF IMPERMEABLE EXOGENOUS MATERIALS (SMALL MOLECULES, PROTEINS AND GENES) WILL BENEFIT DRUG, VACCINE AND GENE THERAPY.
$0
11/1/24
Not listed
TARGETED NANO-ENHANCED OPTICAL DELIVERY OF OPSIN FOR DRY-AMD THERAPY - GEOGRAPHIC ATROPHIES (GA) IN DRY-AGE RELATED MACULAR DEGENERATION (AMD) IS CHARACTERIZED BY DEGENERATION OF PHOTORECEPTORS, AND IS THE LEADING CAUSE OF NEW VISION LOSS IN ~15 MILLION PERSONS. THERE IS NEITHER A CURE THAT CAN STOP THE DEGENERATION NOR A THERAPY TO RESTORE VISION LOSS. WE HAVE DEVELOPED AMBIENT-LIGHT ACTIVATABLE MULTI-CHARACTERISTIC OPSIN (MCO-II) TO ALLOW STIMULATION OF RETINAL GANGLION CELLS (RGCS) FOR VISION REHABILITATION. HOWEVER, CLINICAL TRANSLATION OF SUCH GENE THERAPY TO PATIENTS WITH GA WILL REQUIRE TARGETED DELIVERY OF OPSIN- ENCODING GENES INTO THE ATROPHIC REGIONS WITHOUT PERTURBING REMAINING FUNCTIONAL RETINA. THEREFORE, WE HAVE DEVELOPED A NEAR-INFRARED LASER BASED EFFICIENT METHOD FOR IN-VIVO TARGETED GENE DELIVERY INTO RETINA. IN THIS NANO-ENHANCED OPTICAL DELIVERY (NOD) METHOD, WE UTILIZE SURFACE PLASMON RESONANCE BASED FIELD ENHANCEMENT BY FUNCTIONALIZED GOLD NANORODS (FGNRS) TO TRANSIENTLY PERFORATE CELL MEMBRANE TO DELIVER THE MOLECULES. IN THE PHASE I, WE DEMONSTRATED TARGETED IN-VIVO OPTICAL DELIVERY OF MCO-II TO DEGENERATED RETINA IN MICE USING NOD AT MULTIPLE WAVELENGTHS. FURTHER, WE MADE COMPARATIVE STUDY OF CONTINUOUS WAVE (CW) AND NANOSECOND PULSED LASER BASED NOD OF MCO-II PLASMIDS AND DETERMINED OPTIMIZED LASER PARAMETERS FOR EFFICIENT TRANSFECTION OF RETINA. NO DETECTABLE OCULAR DAMAGE WAS OBSERVED DUE TO NOD. FURTHER, THE IMMUNOSTAINING OF RETINA AFTER IN-VIVO NOD OF MCO-II PLASMIDS SHOWED NO NOTICEABLE CELL DEATH. ELECTROPHYSIOLOGY STUDIES DEMONSTRATE THAT MCO-II SENSITIZED CELLS ARE ACTIVATABLE BY LIGHT, ALLOWING VISUALLY EVOKED CORTICAL ACTIVITIES. THE OVERALL GOAL OF THIS PHASE-II PROPOSAL IS TO DEVELOP THE COMBINATION NOD PRODUCT FOR PHOTOSENSITIZING RGCS IN THE DEGENERATED RETINA IN A SAFE MANNER AND STIMULATING PHOTOSENSITIZED RGCS BY AMBIENT LIGHT FOR VISION REHABILITATION. TOWARDS THIS GOAL WE HAVE FOLLOWING AIMS: (1) QUANTIFY LONG-TERM STABILITY AND SAFETY OF NOD IN MICE MODEL LACKING PHOTORECEPTORS; (2) EVALUATE FUNCTIONING OF TARGETED RETINAL REGIONS AFTER RE-PHOTOSENSITIZATION OF RGCS USING NOD ASSISTED MCO-II DELIVERY IN MICE AND RAT MODELS; AND (3) GLP STUDY OF TOXICITY, BIODISTRIBUTION AND EFFICACY OF NOD-DELIVERED MCO-II PLASMIDS IN NON-HUMAN PRIMATES (NHPS). THIS COLLABORATIVE PROPOSAL BRINGS TOGETHER COMPLEMENTARY EXPERTISE IN OPTICAL DELIVERY, OPTOGENETICS, OPHTHALMOLOGY, INSTRUMENT, MOLECULAR BIOLOGY, NANOMATERIALS, RETINA BIOLOGY AND FUNCTION, NEUROSCIENCE/BEHAVIOR, ELECTROPHYSIOLOGY, BIOSTATISTICS, AND TOXICOLOGY TO ADDRESS THE CHALLENGE IN RETINAL DEGENERATION. THE SAFETY/EFFICACY STUDY IN NHPS WILL BE PERFORMED AT CRO FACILITY. UPON COMPLETION OF THE PHASE II WE ENVISION TO ADVANCE: (I) NOD PRODUCT DEVELOPMENT FOR CLINICAL STUDIES, (II) IND APPLICATION TO FDA, AND (III) PARTNERING WITH VENTURE CAPITAL AND PHARMA COMPANY FOR COMMERCIALIZATION. SUCCESS OF THIS PROPOSAL WILL LEAD TO A NEW CLINICAL APPROACH FOR TREATING PATIENTS WITH GA BY CONVENTIONAL INTRAVITREAL INJECTION OF FGNRS AND MCO-II. THE NOD BASED TARGETED DELIVERY OF IMPERMEABLE EXOGENOUS MATERIALS (SMALL MOLECULES, PROTEINS AND GENES) WILL BENEFIT DRUG, VACCINE AND GENE THERAPY.
$0
11/1/24
Not listed
TARGETED NANO-ENHANCED OPTICAL DELIVERY OF OPSIN FOR DRY-AMD THERAPY - GEOGRAPHIC ATROPHIES (GA) IN DRY-AGE RELATED MACULAR DEGENERATION (AMD) IS CHARACTERIZED BY DEGENERATION OF PHOTORECEPTORS, AND IS THE LEADING CAUSE OF NEW VISION LOSS IN ~15 MILLION PERSONS. THERE IS NEITHER A CURE THAT CAN STOP THE DEGENERATION NOR A THERAPY TO RESTORE VISION LOSS. WE HAVE DEVELOPED AMBIENT-LIGHT ACTIVATABLE MULTI-CHARACTERISTIC OPSIN (MCO-II) TO ALLOW STIMULATION OF RETINAL GANGLION CELLS (RGCS) FOR VISION REHABILITATION. HOWEVER, CLINICAL TRANSLATION OF SUCH GENE THERAPY TO PATIENTS WITH GA WILL REQUIRE TARGETED DELIVERY OF OPSIN- ENCODING GENES INTO THE ATROPHIC REGIONS WITHOUT PERTURBING REMAINING FUNCTIONAL RETINA. THEREFORE, WE HAVE DEVELOPED A NEAR-INFRARED LASER BASED EFFICIENT METHOD FOR IN-VIVO TARGETED GENE DELIVERY INTO RETINA. IN THIS NANO-ENHANCED OPTICAL DELIVERY (NOD) METHOD, WE UTILIZE SURFACE PLASMON RESONANCE BASED FIELD ENHANCEMENT BY FUNCTIONALIZED GOLD NANORODS (FGNRS) TO TRANSIENTLY PERFORATE CELL MEMBRANE TO DELIVER THE MOLECULES. IN THE PHASE I, WE DEMONSTRATED TARGETED IN-VIVO OPTICAL DELIVERY OF MCO-II TO DEGENERATED RETINA IN MICE USING NOD AT MULTIPLE WAVELENGTHS. FURTHER, WE MADE COMPARATIVE STUDY OF CONTINUOUS WAVE (CW) AND NANOSECOND PULSED LASER BASED NOD OF MCO-II PLASMIDS AND DETERMINED OPTIMIZED LASER PARAMETERS FOR EFFICIENT TRANSFECTION OF RETINA. NO DETECTABLE OCULAR DAMAGE WAS OBSERVED DUE TO NOD. FURTHER, THE IMMUNOSTAINING OF RETINA AFTER IN-VIVO NOD OF MCO-II PLASMIDS SHOWED NO NOTICEABLE CELL DEATH. ELECTROPHYSIOLOGY STUDIES DEMONSTRATE THAT MCO-II SENSITIZED CELLS ARE ACTIVATABLE BY LIGHT, ALLOWING VISUALLY EVOKED CORTICAL ACTIVITIES. THE OVERALL GOAL OF THIS PHASE-II PROPOSAL IS TO DEVELOP THE COMBINATION NOD PRODUCT FOR PHOTOSENSITIZING RGCS IN THE DEGENERATED RETINA IN A SAFE MANNER AND STIMULATING PHOTOSENSITIZED RGCS BY AMBIENT LIGHT FOR VISION REHABILITATION. TOWARDS THIS GOAL WE HAVE FOLLOWING AIMS: (1) QUANTIFY LONG-TERM STABILITY AND SAFETY OF NOD IN MICE MODEL LACKING PHOTORECEPTORS; (2) EVALUATE FUNCTIONING OF TARGETED RETINAL REGIONS AFTER RE-PHOTOSENSITIZATION OF RGCS USING NOD ASSISTED MCO-II DELIVERY IN MICE AND RAT MODELS; AND (3) GLP STUDY OF TOXICITY, BIODISTRIBUTION AND EFFICACY OF NOD-DELIVERED MCO-II PLASMIDS IN NON-HUMAN PRIMATES (NHPS). THIS COLLABORATIVE PROPOSAL BRINGS TOGETHER COMPLEMENTARY EXPERTISE IN OPTICAL DELIVERY, OPTOGENETICS, OPHTHALMOLOGY, INSTRUMENT, MOLECULAR BIOLOGY, NANOMATERIALS, RETINA BIOLOGY AND FUNCTION, NEUROSCIENCE/BEHAVIOR, ELECTROPHYSIOLOGY, BIOSTATISTICS, AND TOXICOLOGY TO ADDRESS THE CHALLENGE IN RETINAL DEGENERATION. THE SAFETY/EFFICACY STUDY IN NHPS WILL BE PERFORMED AT CRO FACILITY. UPON COMPLETION OF THE PHASE II WE ENVISION TO ADVANCE: (I) NOD PRODUCT DEVELOPMENT FOR CLINICAL STUDIES, (II) IND APPLICATION TO FDA, AND (III) PARTNERING WITH VENTURE CAPITAL AND PHARMA COMPANY FOR COMMERCIALIZATION. SUCCESS OF THIS PROPOSAL WILL LEAD TO A NEW CLINICAL APPROACH FOR TREATING PATIENTS WITH GA BY CONVENTIONAL INTRAVITREAL INJECTION OF FGNRS AND MCO-II. THE NOD BASED TARGETED DELIVERY OF IMPERMEABLE EXOGENOUS MATERIALS (SMALL MOLECULES, PROTEINS AND GENES) WILL BENEFIT DRUG, VACCINE AND GENE THERAPY.
$0
3/15/24
Not listed
TARGETED NANO-ENHANCED OPTICAL DELIVERY OF OPSIN FOR DRY-AMD THERAPY - GEOGRAPHIC ATROPHIES (GA) IN DRY-AGE RELATED MACULAR DEGENERATION (AMD) IS CHARACTERIZED BY DEGENERATION OF PHOTORECEPTORS, AND IS THE LEADING CAUSE OF NEW VISION LOSS IN ~15 MILLION PERSONS. THERE IS NEITHER A CURE THAT CAN STOP THE DEGENERATION NOR A THERAPY TO RESTORE VISION LOSS. WE HAVE DEVELOPED AMBIENT-LIGHT ACTIVATABLE MULTI-CHARACTERISTIC OPSIN (MCO-II) TO ALLOW STIMULATION OF RETINAL GANGLION CELLS (RGCS) FOR VISION REHABILITATION. HOWEVER, CLINICAL TRANSLATION OF SUCH GENE THERAPY TO PATIENTS WITH GA WILL REQUIRE TARGETED DELIVERY OF OPSIN- ENCODING GENES INTO THE ATROPHIC REGIONS WITHOUT PERTURBING REMAINING FUNCTIONAL RETINA. THEREFORE, WE HAVE DEVELOPED A NEAR-INFRARED LASER BASED EFFICIENT METHOD FOR IN-VIVO TARGETED GENE DELIVERY INTO RETINA. IN THIS NANO-ENHANCED OPTICAL DELIVERY (NOD) METHOD, WE UTILIZE SURFACE PLASMON RESONANCE BASED FIELD ENHANCEMENT BY FUNCTIONALIZED GOLD NANORODS (FGNRS) TO TRANSIENTLY PERFORATE CELL MEMBRANE TO DELIVER THE MOLECULES. IN THE PHASE I, WE DEMONSTRATED TARGETED IN-VIVO OPTICAL DELIVERY OF MCO-II TO DEGENERATED RETINA IN MICE USING NOD AT MULTIPLE WAVELENGTHS. FURTHER, WE MADE COMPARATIVE STUDY OF CONTINUOUS WAVE (CW) AND NANOSECOND PULSED LASER BASED NOD OF MCO-II PLASMIDS AND DETERMINED OPTIMIZED LASER PARAMETERS FOR EFFICIENT TRANSFECTION OF RETINA. NO DETECTABLE OCULAR DAMAGE WAS OBSERVED DUE TO NOD. FURTHER, THE IMMUNOSTAINING OF RETINA AFTER IN-VIVO NOD OF MCO-II PLASMIDS SHOWED NO NOTICEABLE CELL DEATH. ELECTROPHYSIOLOGY STUDIES DEMONSTRATE THAT MCO-II SENSITIZED CELLS ARE ACTIVATABLE BY LIGHT, ALLOWING VISUALLY EVOKED CORTICAL ACTIVITIES. THE OVERALL GOAL OF THIS PHASE-II PROPOSAL IS TO DEVELOP THE COMBINATION NOD PRODUCT FOR PHOTOSENSITIZING RGCS IN THE DEGENERATED RETINA IN A SAFE MANNER AND STIMULATING PHOTOSENSITIZED RGCS BY AMBIENT LIGHT FOR VISION REHABILITATION. TOWARDS THIS GOAL WE HAVE FOLLOWING AIMS: (1) QUANTIFY LONG-TERM STABILITY AND SAFETY OF NOD IN MICE MODEL LACKING PHOTORECEPTORS; (2) EVALUATE FUNCTIONING OF TARGETED RETINAL REGIONS AFTER RE-PHOTOSENSITIZATION OF RGCS USING NOD ASSISTED MCO-II DELIVERY IN MICE AND RAT MODELS; AND (3) GLP STUDY OF TOXICITY, BIODISTRIBUTION AND EFFICACY OF NOD-DELIVERED MCO-II PLASMIDS IN NON-HUMAN PRIMATES (NHPS). THIS COLLABORATIVE PROPOSAL BRINGS TOGETHER COMPLEMENTARY EXPERTISE IN OPTICAL DELIVERY, OPTOGENETICS, OPHTHALMOLOGY, INSTRUMENT, MOLECULAR BIOLOGY, NANOMATERIALS, RETINA BIOLOGY AND FUNCTION, NEUROSCIENCE/BEHAVIOR, ELECTROPHYSIOLOGY, BIOSTATISTICS, AND TOXICOLOGY TO ADDRESS THE CHALLENGE IN RETINAL DEGENERATION. THE SAFETY/EFFICACY STUDY IN NHPS WILL BE PERFORMED AT CRO FACILITY. UPON COMPLETION OF THE PHASE II WE ENVISION TO ADVANCE: (I) NOD PRODUCT DEVELOPMENT FOR CLINICAL STUDIES, (II) IND APPLICATION TO FDA, AND (III) PARTNERING WITH VENTURE CAPITAL AND PHARMA COMPANY FOR COMMERCIALIZATION. SUCCESS OF THIS PROPOSAL WILL LEAD TO A NEW CLINICAL APPROACH FOR TREATING PATIENTS WITH GA BY CONVENTIONAL INTRAVITREAL INJECTION OF FGNRS AND MCO-II. THE NOD BASED TARGETED DELIVERY OF IMPERMEABLE EXOGENOUS MATERIALS (SMALL MOLECULES, PROTEINS AND GENES) WILL BENEFIT DRUG, VACCINE AND GENE THERAPY.
$0
3/15/24